NasdaqCM - Nasdaq Real Time Price • USD
Catalyst Pharmaceuticals, Inc. (CPRX)
As of 12:59 PM EDT. Market Open.
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 5 | 5 | 5 | 5 |
| Avg. Estimate | 0.17 | 0.24 | 1 | 1.42 |
| Low Estimate | 0.14 | 0.2 | 0.85 | 1.27 |
| High Estimate | 0.19 | 0.28 | 1.09 | 1.48 |
| Year Ago EPS | 0.26 | 0.33 | 0.63 | 1 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 7 | 7 | 7 | 7 |
| Avg. Estimate | 98.13M | 111.6M | 460.53M | 548.68M |
| Low Estimate | 91.4M | 108.66M | 455.3M | 517.97M |
| High Estimate | 103.53M | 116.18M | 467.55M | 604.57M |
| Year Ago Sales | 85.37M | -- | 398.2M | 460.53M |
| Sales Growth (year/est) | 15.00% | -- | 15.70% | 19.10% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | 0.32 | 0.36 | -0.28 | 0.26 |
| EPS Actual | 0.26 | 0.33 | -0.29 | 0.31 |
| Difference | -0.06 | -0.03 | -0.01 | 0.05 |
| Surprise % | -18.80% | -8.30% | -3.60% | 19.20% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 0.17 | 0.24 | 1 | 1.42 |
| 7 Days Ago | 0.17 | 0.24 | 1 | 1.41 |
| 30 Days Ago | 0.24 | 0.3 | 1.16 | 1.53 |
| 60 Days Ago | 0.24 | 0.29 | 1.2 | 1.61 |
| 90 Days Ago | 0.24 | 0.29 | 1.2 | 1.61 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | 1 | 1 |
| Up Last 30 Days | -- | -- | 1 | 1 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | 1 | -- | -- |
Growth Estimates
| CURRENCY IN USD | CPRX | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -34.60% | -- | -- | 1.50% |
| Next Qtr. | -27.30% | -- | -- | 12.10% |
| Current Year | 58.70% | -- | -- | 4.40% |
| Next Year | 42.00% | -- | -- | 13.20% |
| Next 5 Years (per annum) | -- | -- | -- | 10.97% |
| Past 5 Years (per annum) | 36.62% | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | Oppenheimer: Outperform to Outperform | 3/27/2024 |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 3/22/2024 |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 3/14/2024 |
| Initiated | Citigroup: Buy | 3/14/2024 |
| Initiated | B of A Securities: Buy | 3/7/2024 |
| Maintains | Cantor Fitzgerald: Overweight to Overweight | 3/1/2024 |
Related Tickers
AXSM Axsome Therapeutics, Inc.
71.70
+0.25%
DAWN Day One Biopharmaceuticals, Inc.
14.96
+13.24%
ARDX Ardelyx, Inc.
6.55
+3.72%
HALO Halozyme Therapeutics, Inc.
38.74
+0.73%
XFOR X4 Pharmaceuticals, Inc.
1.0500
-7.08%
LGND Ligand Pharmaceuticals Incorporated
71.48
+1.58%
EWTX Edgewise Therapeutics, Inc.
16.74
+5.02%
AUPH Aurinia Pharmaceuticals Inc.
4.9250
+1.13%
OCUP Ocuphire Pharma, Inc.
1.6000
+4.23%
VNDA Vanda Pharmaceuticals Inc.
4.5800
+2.23%